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Abstract
Purpose To evaluate the effect of intra-
silicone injection of bevacizumab for the
treatment of neovascular glaucoma (NVG)
after vitrectomy for advanced proliferative
diabetic retinopathy.
Methods Bevacizumab was injected into the
silicone oil in five pseudophakic eyes of five
patients with NVG. The iris
neovascularization (INV) and NVG had
developed 1.5–4 months after vitrectomy and
silicone oil tamponade. The main outcome
measures were regression of INV, intraocular
pressure and visual acuity.
Results In all eyes, INV regressed and
intraocular pressure was controlled within
7 days. Visual acuity improved in all eyes. In
one patient, INV and NVG recurred 10 weeks
after the injection and was successfully treated
with a repeat intra-silicone bevacizumab
injection.
Conclusion Intra-silicone injection of
bevacizumab is effective in the treatment of
patients with INV and NVG after vitrectomy
for advanced proliferative diabetic
retinopathy.
Eye (2010) 24, 717–719; doi:10.1038/eye.2009.94;
published online 1 May 2009
Keywords: bevacizumab; silicone oil; vitrectomy;
neovascular glaucoma; diabetic retinopathy
Introduction
Vascular endothelial growth factor (VEGF)
plays a central role in several ocular pathologies
characterized by neovascularization and
increased vascular permeability.1 Neovascular
glaucoma (NVG) is a devastating complication
associated with ischaemic retinopathies such as
diabetic retinopathy.2 Standard treatment
includes retinal photocoagulation and
cyclodestructive or drainage procedures.3
Several studies have reported the value of
intraocular anti-VEGF therapy with
bevacizumab as a treatment for iris
neovascularization (INV) associated with
glaucoma.4–7
Silicone oil is an important adjunct in
the management of complex vitreoretinal
surgical procedures. It has been extensively
used as a tamponade in cases in which
conventional vitreoretinal surgery is likely to
result in a poor success rate.8 In the presence
of silicone oil tamponade, the delivery and
concentration of drugs injected into the
posterior segment of the eye become
unpredictable.
The aim of this pilot study was to investigate
the value of intraocular anti-VEGF therapy with
bevacizumab as a treatment for INV associated
with glaucoma after vitrectomy and silicone
oil tamponade for the treatment of advanced
diabetic retinopathy.
Patients and methods
During a 12-month period, five eyes of five
consecutive patients with the entry criterion
of clinical INV associated with NVG were
prospectively studied. They had earlier
undergone vitreoretinal surgery, including
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complete panretinal endophotocoagulation and silicone
oil endotamponade for the treatment of severe
proliferative diabetic retinopathy (PDR). All patients
received injections of 2.5 mg bevacizumab (0.1 mg of
commercially available Avastin solution; Genentech Inc.
(made for F Hoffmann-La Roche Ltd, Basel,
Switzerland)) into the silicone-filled vitreous cavity.
Patients had to have at least 3 months of follow-up
after intra-silicone injection of bevacizumab for
inclusion in the study.
Exclusion criteria were the presence of any tractional
and/or rhegmatogenous retinal detachment, active
intraocular inflammation or signs of earlier
inflammation, such as iris-intraocular lens synechiae
or clinically obvious macular oedema, and intraocular
pressure (IOP) of more than 22 mm Hg before the
appearance of INV. Also, patients with more than
3 days of delay between INV detection and intraocular
bevacizumab injection were excluded.
The characteristics of the disease, lack of any treatment
other than cycloablation, the experimental nature of
the study, and the off-label use of bevacizumab were
explained to the patients and informed consent was
obtained. The institutional review board/ethics
committee of the Eye Research Center approved the
study.
Ophthalmic examinations included visual acuity
testing, slit lamp biomicroscopy, measurement of
IOP, and dilated funduscopy. Paraclinical evaluation
included slit lamp and fundus photography. The patients
were visited on the first day after injection and at
3 days, 1 week, and monthly thereafter depending
on the involution of INV and IOP control. The
examination protocol was repeated for all post-operative
visits.
Results
Five pseudophakic eyes with a mean age of 62.4±7.6
years were studied. Table 1 shows the patient
characteristics. The INV and NVG developed 1.5–4
months after vitrectomy and silicone oil tamponade.
In all cases, the INV completely disappeared clinically
within 7 days, starting almost 72 h after injection. Visual
acuity improved in all eyes. The mean visual acuity
improved from 1.7±0.2 LogMAR before injections to
1.5±0.3 LogMAR at the final examination (P¼ 0.02). The
mean IOP before intra-silicone injections was 34 mm Hg
(range 25–45) despite maximum anti-glaucoma therapy.
In all cases, the IOP decreased within 72 h and returned
to levels o20 mm Hg with timolol and dorzolamide
within 7 days. No inflammation or other complications
were observed. INV recurrence associated with IOP
elevation was detected in one patient 10 weeks after
injection, which regressed after intra-silicone reinjection
of bevacizumab.
Discussion
Intraocular administration of bevacizumab has been
shown to induce rapid regression of neovascularization
in diabetic eyes.4,7 It may be an advantageous treatment
option in the eyes in which fundus-obscuring cataract or
vitreous haemorrhage prevents photocoagulation, and in
eyes in which INV is not halted by panretinal
photocoagulation.3,4,7
INV and NVG are rarely encountered after
vitreoretinal surgery for complications of PDR. So far, no
treatment has been available for regression of
neovascularization in these patients because retinal
photocoagulation has already been carried out before


























62/M 8 7 4 2 m FC 20/400 20/400 30 18 16/tinolol,
dorzolamide
71/F 6 7 9 LP HM HM 45 19 16/tinolol,
dorzolamide,
brimonidine
53/M 16 7 4 1 m FC 20/400 2 m FC 30 18 15/tinolol,
dorzolamide
Recurrence
57/F 10 3 3 2 m FC 20/400 20/400 25 15 16/timolol
69/F 32 7 3 HM HM 1 m FC 40 18 18/tinolol,
dorzolamide
INV, iris neovascularization; BCVA, best corrected visual acuity; IOP, intraocular pressure; M, male; F, female; HM, hand movement; FC, fingers counting;
LP, light perception.
aPre-injection intraocular pressure with timolol, dorzolamide, brimonidine eye drops, and oral acetazolamide.
bIntraocular pressure at 1 week after injection with timolol and dorzolamide.
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and/or during the surgery. Therefore, the treatment of
NVG in these patients has been mainly limited to
cycloablative procedures as drainage procedures are
often unsuccessful in the presence of active NVI.3
We observed a uniformly good response to intra-
silicone injection of bevacizumab in this series of five
patients with NVG after vitreoretinal surgery for
advanced PDR. We therefore conclude that this injection
may be the treatment of choice for these patients, and we
recommend it as soon as possible after the appearance of
active INV and NVG, as delayed treatment may result in
peripheral anterior synechiae formation complicating the
clinical picture.
The rapid diffusion of bevacizumab out of silicone oil,
as evidenced by dramatic clinical response in our
patients, also has other important implications. Many
vitreoretinal surgeons inject bevacizumab intravitreally
at the end of vitrectomy for PDR without tamponade.9
Our results indicate that it can also be injected at the end
of surgery for severe cases where silicone tamponade
is used, and it may help to induce regression of
the remaining new vessels as well as serve as an
anti-inflammatory agent.10
We injected 2.5 mg bevacizumab into the silicone oil
instead of the more commonly used dose of 1.25 mg. The
2.5-mg dose has been used by several investigators for
the treatment of choroidal neovascularization and
diabetic macular oedema, and has been found to have the
same or higher efficacy as compared with the 1.25-mg
dose, without significant side effects.11–13 In addition,
we were not certain about the efficacy of bevacizumab
injected inside the silicone oil, and therefore we thought
we might have more bevacizumab molecules reaching
the retinal periphery with this higher dose. It is quite
likely that the regular 1.25 mg dose may have the same
efficacy in regressing INV.
Another point to be considered is that bevacizumab,
which diffuses out of the silicone oil, may accumulate in
the inferior meniscus of the fluid underneath silicone oil
by gravity. We cannot speculate about the concentration
of bevacizumab in this fluid meniscus, but we did not
observe any sign of clinical toxicity in these patients.
Concentrations up to 5 mg in the vitreous cavity have not
been associated with histologic or electroretinographic
signs of toxicity in rabbit eyes.14 Our group has studied
the effects of higher doses of intravitreal bevacizumab
injections in rabbit eyes and did not observe any sign of
toxicity after injections up to 7.5 mg (Modarres et al.,
unpublished data).
The small size of this study is partly because of the fact
that the occurrence of NVG in post-diabetic vitrectomy
eyes with silicone oil is a rarely observed complication.
Larger studies with longer follow-up are required to
further validate these findings.
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